Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Public ClinicalTrials.gov record NCT06084481. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
Study identification
- NCT ID
- NCT06084481
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 302 participants
Conditions and interventions
Conditions
- Biliary Tract Cancers
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous-Cell Carcinoma
- Hepatocellular Carcinoma
- Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- Pancreatic Ductal Adenocarcinoma
- Platinum Resistant High Grade Epithelial Ovarian Cancer
- Triple Negative Breast Cancer
Interventions
- ABBV-400 Drug
- Itraconazole (ITZ) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 8, 2023
- Primary completion
- Jun 30, 2026
- Completion
- Jun 30, 2026
- Last update posted
- Jan 19, 2026
2023 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center /ID# 258645 | Duarte | California | 91010 | — |
| Ucsf /Id# 257705 | San Francisco | California | 94143 | — |
| University of Colorado Cancer Center - Cancer Clinical Trials Office /ID# 255128 | Aurora | Colorado | 80045-7158 | — |
| Sarah Cannon Research Institute at HealthONE - Denver /ID# 258926 | Denver | Colorado | 80218 | — |
| Florida Cancer Specialists /ID# 261569 | Sarasota | Florida | 34232 | — |
| Northwestern University Feinberg School of Medicine /ID# 257378 | Chicago | Illinois | 60611-2927 | — |
| University of Chicago Medical Center /ID# 258197 | Chicago | Illinois | 60637 | — |
| START Midwest /ID# 256581 | Grand Rapids | Michigan | 49546-7062 | — |
| Washington University-School of Medicine /ID# 257379 | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center-Koch Center /ID# 255132 | New York | New York | 10065-6007 | — |
| Duke Cancer Center /ID# 255129 | Durham | North Carolina | 27710 | — |
| Univ Hosp Cleveland /ID# 257706 | Cleveland | Ohio | 44106 | — |
| Lifespan Cancer Institute at Rhode Island Hospital /ID# 257693 | Providence | Rhode Island | 02903-4923 | — |
| MUSC Hollings Cancer Center /ID# 257935 | Charleston | South Carolina | 29425 | — |
| Prisma Health /ID# 257697 | Greenville | South Carolina | 29605 | — |
| Tennessee Oncology-Nashville Centennial /ID# 261568 | Nashville | Tennessee | 37203-1632 | — |
| MD Anderson Cancer Center /ID# 255131 | Houston | Texas | 77030 | — |
| Univ Texas HSC San Antonio /ID# 257708 | San Antonio | Texas | 78229-3901 | — |
| South Texas Accelerated Research Therapeutics /ID# 260404 | San Antonio | Texas | 78229 | — |
| Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 262771 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06084481, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06084481 live on ClinicalTrials.gov.